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Although fatty acid binding protein 4 (FABP4) may increase risk of diabetes and exert negative cardiac inotropy, it is unknown
whether plasma concentrations of FABP4 are associated with incidence of sudden cardiac death (SCD). We prospectively analyzed
dataon4,560participantsoftheCardiovascularHealthStudy.FABP4wasmeasuredatbaselineusingELISA,andSCDeventswere
adjudicated through review of medical records. We used Cox proportional hazards to estimate effect measures. During a median
followupof11.8years,146SCDcasesoccurred.Inamultivariablemodeladjustingfordemographic,lifestyle,andmetabolicfactors,
relativeriskofSCDassociatedwitheachhigherstandarddeviation(SD)ofplasmaFABP4was1.15(95%CI:0.95–1.38),𝑃 = 0.15.Ina
secondaryanalysisstratifiedbyprevalentdiabetesstatus,FABP4wasassociatedwithhigherriskofSCDinnondiabeticparticipants,
(RRperSDhigherFABP4:1.33(95%CI:1.07–1.65),𝑃 = 0.009)butnotindiabeticparticipants(RRperSDhigherFABP4:0.88(95%
CI: 0.62–1.27), 𝑃 = 0.50), 𝑃 f o rd i a b e t e s - F A B P 4i n t e r a c t i o n0 . 0 4 9 .I ns u m m a r y ,as i n g l em e a s u r eo fp l a s m aF A B P 4o b t a i n e dl a t e r
in life was not associated with the risk of SCD in older adults overall. Confirmation of our post-hoc results in nondiabetic people
in other studies is warranted.
1. Introduction
Eachyear,nearlyhalfamillionsuddencardiacdeaths(SCDs)
occur in the US [1, 2]. Although more than 80% of SCDs
occur in patients with coronary heart disease or congestive
heart failure, conditions strongly linked to adiposity [3–5],
several traditional adiposity-related risk factors such as high
cholesterol or high blood pressure are not strongly predictive
of SCD. Adiposity [6] and metabolic syndrome [7]h a v e
been positively associated with an increased QT dispersion,2 Cardiology Research and Practice
another risk factor for SCD [8–10]. Furthermore, weight loss
may lead to a decrease in QT dispersion [11], suggesting that
adiposity may influence the risk of SCD.
Adipose tissues produce various adipokines including
fatty acid binding protein 4 (FABP4)—also referred to as aP2
or a FABP, a carrier protein that transports fatty acids and
other lipophilic substances between extra- and intracellular
membranes [12–14] and exerts diverse effects on modulation
of inflammation, thrombogenicity, insulin resistance, and
other metabolic pathways [15–18]. In isolated rat cardiomy-
ocytes, FABP4 acutely depressed shortening amplitude and
intracellular systolic peak Ca(2+) in a dose-response fashion
[19]. This suggests that FABP4 may play an important role
in cardiac depolarization and possibly cardiac arrhythmias.
However, to our knowledge, no data are available in humans
on the effects of FABP4 on cardiac arrhythmia. Because
FABP4 may also increase the risk of type 2 diabetes, it is pos-
s i b l eth a tpeo p l ew i thd i a be t e sm a ybea tah i gh e rri s ko fS C D
than nondiabetic individuals. Furthermore, while limited
a n di n c o n s i s t e n td a t ah a v eb e e nr e p o r t e do nt h ea s s o c i a t i o n
between body mass index and SCD among heart failure
subjects (no association) [20]o rp o s t m y o c a r d i a li n f a r c t i o n
(41% increased risk of SCD per 5 unit decrease in BMI) [21]
patients, no previous study has examined whether FABP4
influences the risk of SCD in a community setting. Under-
s t a n d i n gt h er o l eo fF A B P 4o nS C Di si m p o r t a n ta sF A B P 4
could potentially serve as a novel pharmacological target in
the prevention of SCD. Therefore, we sought to examine the
association between plasma FABP4 and incident SCD.
2. Methods
2.1. Study Population. The Cardiovascular Health Study
(CHS) is a prospective, population-based cohort study of
cardiovasculardiseaseinolderadults.In1989-1990,5201men
and women aged 65years were recruited from a random
sample of Medicare-eligible residents in the following 4 US
communities: Forsyth County, NC; Sacramento County, CA;
Washington County, MD; and Allegheny County, PA. A sup-
plemental cohort of 687 predominantly African-Americans
was recruited in 1992-1993 from three of the same commu-
nities (excepting Washington County) by using the same
sampling and recruitment methods. The institutional review
board of each center approved the study, and all participants
gave written informed consent to participate in the study.
Details of the study design, sampling, and recruitment have
been published [22]. The 1992-93 examination served as the
baseline for this analysis. Of the 4,707 participants for whom
FABP4 measurements were available, we excluded 147 who
were missing covariates included in the main analysis (final
sample of 4560 subjects for current analyses). In a secondary
analysis involving prevalent diabetes, an additional 77 par-
ticipants were excluded due to missing diabetes status at the
s t u d yb a s e l i n e ,r e d u c i n gt h es a m p l et o4 4 8 3i n d i v i d u a l s .
2.2. Measurement of Plasma FABP4. Plasma samples col-
lected at the 1992-1993 examination were stored at −70
∘C
until analyzed at the central laboratory at the University of
Vermont. Plasma FABP4 concentration was measured using
standard ELISA kits (BioVendor ELISA). The inter-assay
coefficient of variation was 2.61% to 5.32% (detectable range
5t o2 5 0n g / m L ) .
2.3. Assessment of SCD in the Cardiovascular Health Study.
Details on ascertainment and classification of cardiovascular
events and deaths in CHS have been published previously
[23, 24]. Cause of death was adjudicated by a centralized
CHS Events Subcommittee by review of death certificates,
inpatient medical records, nursing home or hospice records,
physician questionnaires, interviews with next-of-kin, and
autopsy records, where available. SCD was defined as a
suddenpulselesscondition,presumedduetocardiacarrhyth-
mia, in a previously stable individual that occurred out of
the hospital or in the emergency room. For unwitnessed
deaths, the participant must have been seen within 24hours
of the arrest in a stable condition and without evidence
of a noncardiac cause of cardiac arrest. By definition, SCD
cases could not be under hospice or nursing home care
or have a life-threatening noncardiac comorbidity. Medical
records for all cardiac deaths adjudicated by the CHS Events
Subcommittee were further reviewed by a cardiologist in
order to identify and classify SCD cases. A blinded second
physician review of a random sample of 70 of these death
records showed an 88% inter-reviewer agreement and 𝜅=
0.74 for SCD. SCD was classified as definite, probable, or
possible, depending on the level of evidence available. Initial
analyses were restricted to definite or probable SCDs. The
presentanalysisincludedSCDsoccurringthroughJune2006,
the latest date of adjudicated SCD events.
2.4. Other Variables. Aside from age, race and education
which were ascertained in 1989-90 for the participants in
the first enrollment wave, all other covariates used in the
analysis were based on data obtained during the 1992-1993.
Information on age, race, years of education, smoking status,
hormone replacement therapy, general health status, hyper-
tensive medication use, lipid lowering medication use, and
alcohol consumption was based on self-report. Leisure-time
activity(kcal/week)wasassessedusingamodifiedMinnesota
Leisure-Time Activities questionnaire [25]. Weight, height,
and waist circumference were measured using standardized
protocolsbytrainedstudypersonnel.Bodymassindex(BMI)
was calculated as weight in kilograms divided by height in
meters squared. Total cholesterol was measured in fasting
blood samples by standard assays. High-sensitive C-reactive
protein (hsCRP) was measured by standard ELISA, and
glomerular filtration rate was calculated based on cystatin
measurements as previously described [26].
2.5. Statistical Methods. We fit Cox proportional hazards
models to estimate the relative risk (RR) of SCD associated
with an increase of one standard deviation in FABP4 levels
(SD = 18.98n g / m L ) .T i m ea tr i s kw a sc a l c u l a t e da st h e
interval in days from the date of the 1992-93 examination
t ot h ee a r l i e s to fd a t eo fS C D ,d a t eo fd e a t hf r o ma n o t h e r
cause, or the end of SCD followup in 2006. An initialCardiology Research and Practice 3
Table 1: Baseline characteristics of the 4,560 participants according to tertiles of FABP4.
Tertiles of FABP4 (ng/mL)
T1 (low) T2 T3 (high)
𝑁 1,520 1,520 1,520
Mean ± SD 19.4 ± 3.7 30.2 ± 3.2 53.3 ± 21.4
Range [5.8–24.9][ 25.0–36.4][ 36.5–250.0]
Characteristics 𝑃 value
Age (years) 74.8 ± 5.0 74.7 ± 5.3 75.0 ± 5.5 0.29
BMI (kg/m
2) 24.8 ± 3.6 26.6 ± 3.9 29.3 ± 5.5 <0.001
Waist circumference (cm) 93.0 ± 11.0 97.1 ± 11.9 102.8 ± 14.7 <0.001
Male (%) 70.1 37.7 17.9 <0.001
African American (%) 13.8 16.3 20.2 <0.001
Physical activity (kcal/week)
† 1155 [490–2283] 810 [270–1907] 613 [140–1500]< 0.001
Smoking (%)
Never 37.3 46.6 52.1 <0.001
Former 51.3 43.8 39.1
Current 11.4 9.6 8.9
Alcohol consumption (%)
None 46.5 54.2 63.8 <0.001
≤7 drinks per week 38.4 35.4 30.1
>7 drinks per week 15.1 10.4 6.1
Health status (%)
Poor 8.5 6.9 4.4 <0.001
Fair 36.0 31.0 26.2
Good 38.8 43.1 42.7
Very good 15.1 17.2 23.2
Excellent 1.6 1.7 3.4
Less than high school (%) 75.4 74.0 70.0 0.001
Unintentional weight loss (%) 4.9 4.1 6.5 0.05
GFR-cystatin C (mL/min/1.73m
2) 79.4 ± 17.3 73.8 ± 17.3 64.0 ± 18.5 <0.001
hsCRP (mg/L)
† 1.8 [0.87–4.1] 2.6 [1.3–5.4] 4.2 [1.9–8.8]< 0.001
Prevalent coronary disease (%) 21.9 20.1 22.7 0.60
Prevalent heart failure (%) 4.0 5.0 8.9 <0.001
Estrogen use—women (%) 19.6 15.1 10.2 0.01
Hypertension medication (%) 40.4 48.8 63.2 <0.001
Systolic BP 135.0 ± 21.0 136.1 ± 21.7 137.8 ± 21.8 <0.001
Diastolic BP 71.5 ± 11.4 71.8 ± 10.9 70.6 ± 11.8 0.02
Total cholesterol (mg/dL) 192.1 ± 36.1 204.5 ± 36.6 208.8 ± 41.5 <0.001
Lipid lowering medication (%) 5.5 8.5 8.5 0.002
Hypercholesterolemia (%) 41.6 56.1 59.7 <0.001
Data are presented as mean ± SD or percentage, unless specified otherwise; hsCRP: high-sensitive C-reactive protein; GFR: glomerular filtration rate based on
cystatin C.
†Median (interquartile range).
model adjusted for age, sex, race, and field center (Model 1).
A second model additionally adjusted for education (high
school versus less), GFR-cystatin, CRP, physical activity,
alcohol consumption (none, 7 or less drinks per week, more
than 7 per week), smoking (never, former, current), health
status (poor, fair, good, very good, excellent), and hormone
replacement therapy (Model 2). In Model 3, we also adjusted
for body mass index.
Because FABP4 may increase the risk of diabetes and
w o m e nh a v eh i g h e rp l a s m al e v e l st h a nm e n ,w ee x a m i n e d
insecondaryanalysesFABP4-by-diabetesandFABP4-by-sex
interactions using product terms.
Asasensitivityanalysis,weadditionallyadjustedforwaist
circumference in Models 1–3. Given the influence of weight
loss on plasma concentration of FABP4 [27, 28], we repeated
o u rm a i na n a l y s e sa n dt h ea n a l y s i sa d j u s t i n gf o rw a i s t
circumference after exclusion of individuals with cancer,
cardiovascular disease, or reported unintentional weight loss
in the past 12 months (𝑛 = 1821). Unintentional weight
loss was defined as a loss of more than 10pounds not due
to exercise or diet. Subjects who were missing information
on weight loss, diet, or exercise were not considered as
subjects that experienced unintentional weight loss. Lastly,
we additionally controlled for self-reported unintentional
weight change in the multivariable analysis.
To evaluate the effect of coronary heart disease (CHD),
congestive heart failure (CHF), hypertension, and hyper-
cholesterolemia as potential intermediate factors between4 Cardiology Research and Practice
FABP4 and SCD, we fit a model with additional adjustment
for CHD, CHF as well as systolic blood pressure, hyper-
tension medication use, and hypercholesterolemia. Hyperc-
holesterolemia was defined as the use of lipid lowering drugs
or total cholesterol >200mg/dL. We evaluated the validity
of the proportional hazards assumption by using Schoenfeld
residuals and found no meaningful departures. Statistical
analysis was performed in R 2.13.0 (http://www.r-project
.org/).
3. Results
Among 4,560 participants, 2,648 were women (58.1%), and
the mean age at baseline was 74.9 years (range 65 to
98 years). Median plasma FABP4 was 29.97ng/mL (IQR
22.41−40.76), and women had substantially higher concen-
trations of FABP4 (median 35.35ng/mL) than men (median
23.62ng/mL, 𝑃 ≤ 0.001.
Table 1 presents baseline characteristics of participants
according to tertiles of FABP4. Compared with the lowest
t e r t i l eo fF A B P 4 ,t h o s ei nt h eh i g h e s tt e r t i l eh a dh i g h e r
measures of adiposity, 𝑃 ≤ 0.001, and were more likely to
be women, 𝑃 ≤ 0.001,o rA f r i c a n - A m e r i c a n ,𝑃 ≤ 0.001;
persons in the highest tertile of FABP4 were morelikely to be
physically inactive, 𝑃 ≤ 0.001, had higher hsCRP, 𝑃 ≤ 0.001,
and had lower prevalence of current smoking, 𝑃 ≤ 0.001,
alcohol consumption, 𝑃 ≤ 0.001, and self-reported poor
health status, 𝑃 ≤ 0.001.D u r i n gam e d i a nf o l l o w u po f
11.8 years, 146 cases of “definite” or “probable” SCD were
documented. The crude incidence rate of SCD was 3.1,
2.9, and 3.7 cases per 1000 person-years across consecutive
tertiles of FABP4. In a Cox regression model adjusting for
age, sex, and field center, each SD of FABP4 was associated
with a 32% higher risk of SCD (95% CI: 16% to 51%),
𝑃 ≤ 0.001 (Table 2). However, upon additional adjustment
for education, glomerular filtration rate based on cystatin,
hsCRP, leisure time physical activity, hormone replacement
therapy, alcohol intake, self-reported general health status,
smoking, and body mass index, this association was no
longer statistically significant (HR: 1.15 (95% CI: 0.95–1.38)),
𝑃 = 0.15 (Table 2). Adding potential intermediate factors
(congestive heart failure, coronary heart disease, systolic
blood pressure, and use of antihypertensive or cholesterol-
lowering drugs yielded an HR of 1.12 (0.92–1.37), 𝑃 = 0.24.
W h e nw er e p e a t e dt h em a i na n a l y s i sa ft e ri n c l u d i n ga n
additional 74 SCD cases classified as “possible”, we observed
similar results (RR per standard deviation increase of
FABP4 was 1.12 (95% CI: 0.94–1.32), 𝑃 = 0.20 in model
3).
Whencovariateswereexaminedoneatatime,glomerular
filtration rate based on cystatin C was the single important
confounder, attenuating the relative risk from 1.32 (95% CI:
1.16–1.51), 𝑃 ≤ 0.001,t o1 . 1 8( 9 5 %C I :1 . 0 0 – 1 . 4 0 ) ,𝑃=
0.055 (Table 3). Exclusion of 1821 participants with reported
unintentional weight loss over the past year, cancer, and
cardiovascular disease had little effect on the results (RR per
standard deviation higher FABP4 1.18 (95% CI: 0.82–1.69),
𝑃 = 0.35 in model 3).
Table 2: Hazard ratio (95% CI) of SCD per each SD (18.98ng/mL)
increase of FABP4 concentration among CHS participants (𝑛=
4560).
Hazard ratio (95% CI) 𝑃 value
Per one SD higher FABP4
Model 1
∗ 1.32 (1.16–1.51) <0.001
Model 2
∗∗ 1.15 (0.96–1.37) 0.13
Model 3
∗∗∗ 1.15 (0.95–1.38) 0.15
∗Model 1: adjusted for age, sex, race, and field center.
∗∗Model 2: adjusted for variables in model 1 plus education, GFR-cystatin,
hsCRP (log transformed), kcal of leisure time physical activity (log trans-
formed), hormone replacement therapy, alcohol, self-reported health status,
and smoking.
∗∗∗Model 3: adjusted for variables in model 2 plus body mass index.
In secondary analyses stratified by prevalent diabetes,
FABP4 was associated with a higher incidence rate of SCD
in nondiabetic participants, (HR per SD of FABP4: 1.33 (95%
CI: 1.07–1.65), 𝑃 = 0.009) but not in diabetic participants
(HR per SD of FABP4: 0.88 (95% CI: 0.62–1.27), 𝑃 = 0.50), 𝑃
f o rdia bet es-F ABP4in t eractio n0.04 9(Table 4).Therewasno
evidence for interaction by sex (𝑃 for sex-FABP4 interaction
is 0.20, 0.33, 0.33 for models 1–3, resp.), and the positive
association between FABP4 and SCD among nondiabetic
subjects was present in both men (HR: 1.75 (1.35–2.28), 𝑃<
0.001) and women (HR: 1.39 (1.14–1.69), 𝑃 = 0.001)( a n a l y s i s
adjusted for age, race, and clinic). There was no interaction
between BMI and FABP4 on the risk of SCD (𝑃 = 0.32).
Lastly, to explore possible effects of weight change on the
FABP4-SCD relation, we repeated the main analysis using
people with unmissing data on weight change and observed
HR of 1.05 (95% CI: 0.84–1.31) using model 3 without versus
HR of 1.04 (95% CI: 0.83–1.30), 𝑃 = 0.72, with additional
adjustment for weight change.
4. Discussion
In this large prospective study among community-dwelling
US older adults, we observed no association between FABP4
and the risk of SCD. In a post-hoc analysis stratified by
prevalent diabetes, we demonstrated a higher risk of SCD
per SD higher FABP4 in nondiabetics but not in people
with diabetes (𝑃 for interaction 0.049). To the best of our
knowledge, this is the first study to evaluate the association
between FABP4 and SCD.
Despite a lack of direct evidence of an association
b e t w e e nF A B P 4a n dS C Di nh u m a n s ,p r e v i o u ss t u d i e sh a v e
reported associations between FABP4 and risk factors for
SCD, including coronary artery disease. Specifically, Terra
et al. [29] reported a positive association between FABP4
and C-reactive protein, tumor necrosis alpha receptors, and
interleukin-6 in a sample of 81 morbidly obese females. Fur-
thermore, FABP4 has been inversely related to adiponectin
and positively related to adiposity [17], metabolic syndrome
[17, 18, 30], coronary heart disease burden [31–34], and
diabetes [35].
Chronic kidney failure is a major risk factor for coronary
disease [36, 37] and people with impaired kidney functionCardiology Research and Practice 5
Table 3: Effect of each covariate added one at a time on the hazard ratio (95% CI) of SCD per standard deviation (18.98ng/mL) increase in
FABP4.
Model HR (95% CI) 𝑃 value
Model 1 (basic model)
∗ 1.32 (1.16–1.51) <0.001
Added covariates
Less than high school 1.32 (1.16–1.51) <0.001
GFR-cystatin 1.18 (1.00–1.40) 0.055
Serum creatinine 1.35 (1.16–1.57) <0.001
hsCRP 1.27 (1.11–1.46) <0.001
Kcal of leisure time activity (log) 1.32 (1.16–1.51) <0.001
Alcohol consumption 1.32 (1.16–1.50) <0.001
Self-reported health status 1.29 (1.13–1.48) <0.001
Smoking 1.32 (1.17–1.51) <0.001
Estrogen use (women) 1.32 (1.16–1.50) <0.001
Body mass index 1.32 (1.15–1.51) <0.001
Waist circumference 1.30 (1.13–1.50) <0.001
Hypercholesterolemia 1.32 (1.16–1.51) <0.001
Systolic blood pressure 1.32 (1.16–1.50) <0.001
Hypertensive mediation use 1.26 (1.09–1.45) 0.001
Cardiovascular heard disease 1.29 (1.13–1.47) <0.001
Cardiovascular heart failure 1.24 (1.08–1.44) 0.003
Diabetes 1.27 (1.11–1.45) <0.001
∗M o d e l1a d j u s t e df o ra g e ,s e x ,r a c e ,a n dfi e l dc e n t e r .
Table 4: Hazard ratio (95% CI) of SCD per each SD (18.98ng/mL) increase of FABP4 concentration, by diabetes status (𝑛 = 4483).
Diabetics (𝑛 = 682) Nondiabetics (𝑛 = 3801)
HR (95% CI) 𝑃 value HR (95% CI) 𝑃 value 𝑃 interaction
†
Model 1
∗ 0.95 (0.70–1.28) 0.72 1.45 (1.26–1.67) <0.0001 0.056
Model 2
∗∗ 0.81 (0.56–1.17) 0.26 1.35 (1.10–1.65) 0.004 0.050
Model 3
∗∗∗ 0.88 (0.62–1.27) 0.50 1.33 (1.07–1.65) 0.009 0.049
∗Model 1: adjusted for age, sex, race, and field center.
∗∗Model 2: adjusted for variables in model 1 plus GFR-cystatin, hsCRP (log transformed), kcal of leisure time physical activity (log transformed), hormone
replacement therapy, alcohol, health status, and smoking.
∗∗Model 3: adjusted for variables in model 2 plus body mass index.
†Interaction between diabetes status and FABP4.
There were 41 SCDs in diabetic participants and 102 SCDs events in non-diabetic participants.
have been reported to have higher concentrations of FABP4
[38, 39]. In addition, FABP4 has been shown to correlate
with oxidized LDL and poor endothelial function in diabetic
subjects [40]. Oxidized LDL has been reported to induce the
expression of FABP4 mRNA in human macrophages [41].
These data suggest that FABP4 may indirectly influence the
risk of SCD via incident coronary disease. On the other
hand, both adiposity [6] and metabolic syndrome [7]h a v e
been positively associated with an increased QT dispersion,
another risk factor for SCD [8–10]. Furthermore, weight loss
has been shown to decrease QT dispersion [11]. In our study,
exclusionof236subjectswithunintentionalweightlossledto
a slight increased estimate of association (RR per SD higher
FABP4 was 1.15 (95% CI: 0.95, 1.38) before and 1.20 (95% CI:
0.99, 1.47) after such exclusion). This slight change suggests
that people with other comorbidities related to a higher SCD
risk may be prone to experience weight loss and end up in
the reference group, thereby diluting the effect measure. Our
post-hoc results in nondiabetic warrant future confirmation
in other cohorts.
Limited data available in this area are from ex-vivo
experiments. For example, in isolated rat cardiomyocytes,
FABP4 was shown to acutely depress shortening amplitude
and intracellular systolic peak Ca(2+) in a step-wise fashion
[19]. This suggests that FABP4 may play an important role
in cardiac depolarization and possibly cardiac arrhythmias.
FABP4 has been positively associated with conditions that
could increase the risk of SCD including coronary artery
disease [32, 34], metabolic syndrome [17, 42], overall insulin
resistance [43–45], and incident diabetes [35, 46]. Our group
has reported a positive association between FABP4 and
incident heart failure in this cohort [47]. However, our main
analyses do not lend support to the hypothesis that FABP4 is
a major risk factor for SCD in older adults.
The current study has some limitations. We only had a
single measure of plasma FABP4 obtained after the age of6 Cardiology Research and Practice
65years in this cohort. It is unclear whether we would have
obtained similar results with earlier measures of FABP4 (at
younger age). Furthermore, we were not able to account for
change in this biomarker over time, especially those due
to weight change and other factors over time. Weight loss
is associated with a reduction in serum FABP4 in humans
[27, 28] and in our study, subjects in the highest tertile
of FABP4 were more likely to report unintentional weight
loss. Given the observational nature of our study, we are
not able to exclude residual or unmeasured confounding as
alternative explanation of the observed relation. Participants
i no u rs a m p l ew e r ep r e d o m i n a n t l yC a u c a s i a na g e d7 5y e a r s
on average. Hence, our results may not be generalizable to
younger individuals or other ethnic groups. Despite these
limitations, our study has numerous strengths including a
large sample size; a representative sample of older adults;
inclusion of both men and women; the use of a valid and
reproducible method to assess FABP4; a validation of SCD
by cardiologists; availability of data on numerous potential
confounders; and long-term and nearly complete followup.
5. Conclusions
In conclusion, a single measure of plasma FABP4 obtained
l a t e ri nl i f ew a sn o ta s s o c i a t e dw i t ht h er i s ko fS C Di no l d e r
adults.
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